The Children’s Tumor Foundation announced that it will help fund the biotechnology company NFlection Therapeutics’ new phase IIb clinical trial testing the safety and efficacy of NFX-179 in treating patients with cutaneous neurofibromas following positive results from the company’s phase I/IIa trial. NFX-179—a topical treatment for a condition marked by severe, itchy, and painful bumps on or just beneath the skin that may lead to deafness, blindness, bone abnormalities, debilitating pain, and cancer—is a MEK inhibitor designed to shrink cutaneous neurofibromas with minimal side effects. The Children’s Tumor Foundation investment is expected to help build NFlection Therapeutics’ partnerships with patients, clinics, and experts; accelerate NFX-179 testing; and advance the medication toward U.S. Food and Drug Administration approval. “With this investment, we are taking the first step in our new approach to ending neurofibromatosis. [I]t’s time to start directly investing in select impact opportunities … that have the potential of bringing relief to [patients with] neurofibromatosis as quickly as possible,” concluded Gabriel Groisman, JD, Chairman of the Children’s Tumor Foundation Board of Directors.
April 30, 2023